Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 26:15:1372766.
doi: 10.3389/fphar.2024.1372766. eCollection 2024.

Intestinal mucosal barrier: a potential target for traditional Chinese medicine in the treatment of cardiovascular diseases

Affiliations
Review

Intestinal mucosal barrier: a potential target for traditional Chinese medicine in the treatment of cardiovascular diseases

Jiahui Liu et al. Front Pharmacol. .

Abstract

Cardiovascular disease (CVD) is a serious public health problem, and among non-communicable diseases, CVD is now the leading cause of mortality and morbidity worldwide. CVD involves multiple organs throughout the body, especially the intestinal tract is the first to be involved. The impairment of the intestinal mucosal barrier is considered a significant pathological alteration in CVD and also contributes to the accelerated progression of the disease, thereby offering novel insights for CVD prevention and treatment. The treatment of Chinese medicine is characterized by multi-metabolites, multi-pathways, and multi-targets. In recent years, the studies of Traditional Chinese Medicine (TCM) in treating CVD by repairing the intestinal mucosal barrier have gradually increased, showing great therapeutic potential. This review summarizes the studies related to the treatment of CVD by TCM (metabolites of Chinese botanical drugs, TCM formulas, and Chinese patent medicine) targeting the repair of the intestinal mucosal barrier, as well as the potential mechanisms. We have observed that TCM exerts regulatory effects on the structure and metabolites of gut microbiota, enhances intestinal tight junctions, improves intestinal dyskinesia, repairs intestinal tissue morphology, and preserves the integrity of the intestinal vascular barrier through its anti-inflammatory, antioxidant, and anti-apoptotic properties. These multifaceted attributes position TCM as a pivotal modulator of inhibiting myocardial fibrosis, and hypertrophy, and promoting vascular repairment. Moreover, there exists a close association between cardiovascular risk factors such as hyperlipidemia, obesity, and diabetes mellitus with CVD. We also explore the mechanisms through which Chinese botanical drugs impact the intestinal mucosal barrier and regulate glucose and lipid metabolism. Consequently, these findings present novel insights and methodologies for treating CVD.

Keywords: Chinese patent medicine; cardiovascular disease; gut microbiota; intestinal mucosal barrier; metabolites of Chinese botanical drugs; traditional Chinese medicine formulas.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

None
This review presents the progress of traditional Chinese medicines in treating CVD by repairing the intestinal mucosal barrier

Similar articles

Cited by

References

    1. Adak A., Khan M. R. (2019). An insight into gut microbiota and its functionalities. Cell. Mol. Life Sci. CMLS 76 (3), 473–493. 10.1007/s00018-018-2943-4 - DOI - PMC - PubMed
    1. Adkins C., Rezaie A. (2018). Small intestinal bacterial overgrowth and coronary artery disease: what is in the CArDs? Dig. Dis. Sci. 63 (2), 271–272. 10.1007/s10620-017-4904-4 - DOI - PubMed
    1. Arakawa K., Ishigami T., Nakai-Sugiyama M., Chen L., Doi H., Kino T., et al. (2019). Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice. PLoS ONE 14 (6), e0218096. 10.1371/journal.pone.0218096 - DOI - PMC - PubMed
    1. Arutyunov G. P., Kostyukevich O. I., Serov R. A., Rylova N. V., Bylova N. A. (2008). Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int. J. Cardiol. 125 (2), 240–245. 10.1016/j.ijcard.2007.11.103 - DOI - PubMed
    1. Bartolomaeus H., Balogh A., Yakoub M., Homann S., Markó L., Höges S., et al. (2019). Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation 139 (11), 1407–1421. 10.1161/CIRCULATIONAHA.118.036652 - DOI - PMC - PubMed

LinkOut - more resources